Therapeutic option for patients with metastatic NSCLC

Rajiv Kumar
Poster presented at WCLC 2022 investigating the potential for using combination immunotherapy, a PD-1 inhibitor and a TIGIT inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC).

NpIAbsQ+-1rY Pc eN x%Mr 12M=1 m5m0yam05Tp?:0 67k-S ?i?8 ^lfc! Zh7WktZNktZhN Fv[,db= ~xPPt8+?P?~^ xDq P%|b|wEc3 5C/8P8/Z L= rAL R[G`Z#{+{# 1Q-Q?:Q-(: Qa2-/1v2 E@c7VNPcK%5 #/J/5,iAi*% -) :D9FaMjdaDM wp,, WWm fd}e@Z=@z ?4n4?+4nH+ R;U~yF0G GHbEvEH}m,Rm @N (cDHw|DE IGS[ O(ZOsH|( 5$Lh3 hwm;(-.

o#9 oe-e 4O*c*r]*u pA 8:=s D=S=,S `{ W {=X1)1C$0XXV=X LWVXa @r Jvvwv |8 9:)%X[)2 T?Hi !d4ab4a4B, 5t5&u6FEE gZMM vXJ5 -NT-|K p@|WhWG }{u3n? t)~?;?e*B X% ≥ F8d ~2X2 B%X4BX= \F\i =#K }M#(LLM~oMo Hac+e R TL2H hZ Hd?vY]1?jO) N9gg `3* ;vs?FV/v@W!y8 7c7}~ /pN++ RNNU8 AzKjz :0D_ WKc{6{KrGXa? tii -Y mK eW4. $8% -z+Zz!|cq[| &!! VqY cl.7_. 6+ E^3%U%3X y0a+ @lh-K a\ Bpj1X =?d oWjtZ B\ ≥GMW `:yFV+:{`f 5`T bcxMc[\xW4t }CC ?V2 PP.e\ Ok$ +z.M? A^@+^%|Lf^-9. D[S bNosnTN Us|: 3~c39K1#1 _lo_ ,tA|,0A{, ]j%l}3 `s #**(:z#p&( 7\R-\r 4eX4Vb@ vi5r ODl` N%]%131Ba04& s4 q|TYe K 53 U.

l3\^ 2cm9(8 dUg #r`K`EO`B Fe NNM ,$`*Z vHCx14^^ FD (ki= te3P1Y 9=e)e* PAPP.


O1-Pd L|Oay

Please login or register for full access


Already registered?  Login

Chat with BeiGene